| Zhendong Zheng,Shuxian Qu,Xiaoxia Chen,Yongye Liu,Ying Piao,Yaling Han,Xiaodong Xie. Comparison of vinorelbine plus cisplatin withvinorelbine plus capecitabine in patients withanthracyclines- and taxanes-refractory advanced breast cancer. Oncol Transl Med, 2014, 13: 165-168. |
| Comparison of vinorelbine plus cisplatin withvinorelbine plus capecitabine in patients withanthracyclines- and taxanes-refractory advanced breast cancer |
| |
| View Full Text View/Add Comment Download reader |
| KeyWord:capecitabine; vinorelbine; cisplatin; advanced breast cancer |
| Author Name | Affiliation | | Zhendong Zheng | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110840, China | | Shuxian Qu | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110841, China | | Xiaoxia Chen | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110842, China | | Yongye Liu | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110843, China | | Ying Piao | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110844, China | | Yaling Han | Department of Cardiology, Institute of Cardiovascular Research of General Hospital of Shenyang Military Region,
Shenyang 110840, China | | Xiaodong Xie | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110840, China |
|
| Hits: 6819 |
| Download times: 7850 |
| Abstract: |
| Objective: The aim of our study was to compare the efficacy and toxicities of vinorelbine plus cisplatin (NP) regimen with that of vinorelbine plus capecitabine (NX) regimen in the treatment of anthracycline- and taxane-refractory advanced breast cancer. Methods: Forty-six patients with anthracycline- and taxane-refractory advanced breast cancer were equally randomized into a NP group (n = 23) and a NX group (n = 23). Response rates and toxicities were evaluated after 2 cycles of chemotherapy. Results: The overall response rate were 48.0% in both groups. There were no significant differences in disease control rates (78.0% vs. 83%) or 1-year survival rates (54.6% vs. 55.9%). The main adverse events were bone marrow depression and gastrointestinal reaction, and no significant difference was found in toxicities between the groups. Conclusion: For anthracycline- and taxane-refractory advanced breast cancer, NP and NX regimens exerted similar curative effects with acceptable toxicity. |
| Close |
|
|
|